Frost & Sullivan Company of the Year Award Conferred on Medtech SAS ROSA™ represents a true technological innovation in surgical robotics for neurosurgical interventions
LONDON, April 22, 2013 /PRNewswire/ -- Based on its recent analysis of the surgical robotics for neurosurgical interventions market, Frost & Sullivan recognises Medtech SAS with the prestigious 2013 European Company of the Year Award.
Medtech SAS is commended for its innovative ROSA™ system, which successfully addresses the need for an accurate, economical and clinically effective solution for patients requiring neurological interventions.
"As a robotic surgery system, ROSA™ performs the function of a surgical assistant for neurosurgical procedures," notes Frost & Sullivan Healthcare Industry Analyst Beulah Devadason. "The integration of all neurosurgical requirements and the broad range of procedures that can be performed using ROSA™ make it a true technological innovation in the field of neurosurgery."
Preoperative planning, surgical navigation and integration of intraoperative imaging are necessary to ensure a high degree of safety and accuracy in neurosurgery. ROSA™ is perfectly designed to integrate all these important surgical steps but also to incorporate very precise instrument manipulation.
ROSA™ enables open-skull, stereotactic and NeuroEndoscopic surgeries. The combination of planning, navigation and instrument manipulation facilitate shorter surgery times coupled with minimally invasive interventions in a fully frameless environment.
The shortening of procedure times, which may be up to 50 per cent for certain indications, enables tangible cost savings through simplified workflow, shorter operating room time and reduced surgeon workload, thus allowing multiple procedures within the same day. This further enhances the return on investment for hospitals.
"From a patient perspective, ROSA™ supports reduced trauma by doing away with stereotactic frames as well as enabling minimally-invasive interventions for procedures that traditionally required open-skull surgeries," states Devadason. "Therefore, Medtech SAS's ROSA provides superior customer value in robotic neurosurgery."
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in growth strategy and implementation, degree of innovation in technology and products, and leadership in customer value.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Medtech SAS
The primary motivation that inspired Bertin Nahum to launch Medtech in July 2002 was to benefit patients while developing robots capable of assisting surgeons with their difficult tasks.
His prior experience within several major medical robotic companies and his pioneering spirit were pivotal to the development of the latest technology in robotic assisted neurosurgery.
In 2006, Medtech received notice on the International scene with Zimmer's acquisition of their patent portfolio of BRIGIT™, Medtech's first surgical robotic endeavour. Zimmer Inc. is a leading American company in the field of Orthopaedic Surgery and is consequently widely recognized throughout the world.
Medtech's team subsequently designed ROSA™, a new generation of Robotic Surgical assistant dedicated to the field of Neurosurgery. In 2009, ROSA™ received market approval in Europe with the CE Mark as well as FDA approval in the USA and Health Canada Homologation in Canada. Now in place, it works alongside leading neurosurgeons in several hospitals within Europe, North America and Asia.
Headquartered in Montpellier, France, with offices in New York and Canada as well as sales transactions conducted through a dozen distributors worldwide, Medtech has developed an International reach with a presence in about thirty countries.
Today, Medtech has gained a significant position as a key player in the medical robotics field due to constant and dynamic innovations since the company's inception. The company is extending its leadership to other areas of surgery with new products currently under development.
Contact us: firstname.lastname@example.org
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
T: +33 (0)4 67 10 77 40
Best Practices Group
Frost & Sullivan
T: +44 (0) 207 9157862
SOURCE Frost & Sullivan